Literature DB >> 12850650

Treatment of chronic mechanical spinal pain with intravenous pamidronate: a review of medical records.

Marco Pappagallo1, Brenda Breuer, Aaron Schneider, Kevin Sperber.   

Abstract

We explored the effect of intravenous infusions of a bisphosphonate, pamidronate, in the management of chronic mechanical spinal pain, a worldwide public health problem in terms of lost workdays, medical treatment costs, and suffering. Bisphosphonates have an anti-nociceptive effect in animals. In humans, intravenous pamidronate relieves numerous painful conditions, including metastatic bone pain, ankylosing spondylitis, rheumatoid arthritis, and complex regional pain syndrome. We reviewed the charts of 25 patients who had experienced disabling spinal pain for several years, and whom we treated with intravenous pamidronate. None had a history of osteoporotic vertebral fractures or metastatic disease. Pain rating scores decreased in 91% of patients: on a 0-10 numeric rating scale, the mean pain change was -3.6 points and mean percentage change was -41% (P<0.0001). There was no increase in opioid or nonopioid analgesic medications associated with pain relief. The apparent analgesic effect of pamidronate for chronic mechanical spinal pain needs to be confirmed with placebo-controlled trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12850650     DOI: 10.1016/s0885-3924(03)00201-x

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  13 in total

1.  An unusual cause of spinal bone loss detected by DXA scanning.

Authors:  H Davies; M W J Davie
Journal:  Osteoporos Int       Date:  2012-03-30       Impact factor: 4.507

2.  Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study.

Authors:  M Laroche; S Cantogrel; B Jamard; A Constantin; L Zabraniecki; A Cantagrel; B Mazières
Journal:  Clin Rheumatol       Date:  2006-01-04       Impact factor: 2.980

Review 3.  Pharmacologic therapies for complex regional pain syndrome.

Authors:  Sean Mackey; Steven Feinberg
Journal:  Curr Pain Headache Rep       Date:  2007-02

4.  An open study of pamidronate in the treatment of refractory degenerative lumbar spinal stenosis.

Authors:  Joy Feld; Itzhak Rosner; Nina Avshovich; Nina Boulman; Gleb Slobodin; Michael Rozenbaum
Journal:  Clin Rheumatol       Date:  2009-02-14       Impact factor: 2.980

Review 5.  Do bisphosphonates and statins have a role in spondyloarthritis management?

Authors:  Walter P Maksymowych
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

6.  Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.

Authors:  Jun Iwamoto; Tsuyoshi Takeda; Yoshihiro Sato; Mitsuyoshi Uzawa
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

7.  Alendronate improves QOL of postmenopausal women with osteoporosis.

Authors:  Hisaya Kawate; Keizo Ohnaka; Masahiro Adachi; Suminori Kono; Hideyuki Ikematsu; Hisashi Matsuo; Kazumi Higuchi; Takehiko Takayama; Ryoichi Takayanagi
Journal:  Clin Interv Aging       Date:  2010-04-26       Impact factor: 4.458

Review 8.  Pamidronate treatment in rheumatology practice: a comprehensive review.

Authors:  Gleb Slobodin; Itzhak Rosner; Joy Feld; Doron Rimar; Michael Rozenbaum; Nina Boulman; Majed Odeh
Journal:  Clin Rheumatol       Date:  2009-08-19       Impact factor: 2.980

9.  Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance.

Authors:  Takuo Fujita; Mutsumi Ohue; Yoshio Fujii; Akimitsu Miyauchi; Yasuyuki Takagi
Journal:  J Bone Miner Metab       Date:  2009-02-13       Impact factor: 2.626

10.  A pilot trial of intravenous pamidronate for chronic low back pain.

Authors:  Marco Pappagallo; Brenda Breuer; Hung-Mo Lin; James B Moberly; Julia Tai; Christopher Noto; Angela Sanchez; Paolo L Manfredi
Journal:  Pain       Date:  2013-09-21       Impact factor: 6.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.